Trials / Unknown
UnknownNCT00354445
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,000 (planned)
- Sponsor
- Eyetech Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegaptanib sodium (Macugen) |
Timeline
- Start date
- 2006-06-01
- First posted
- 2006-07-20
- Last updated
- 2007-01-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00354445. Inclusion in this directory is not an endorsement.